Commit Biologics, a Danish biotech company that designs antibodies to point the immune system's complement proteins at diseased cells, has completed a $60m (€54m) seed financing. The company announced the final close of the round on 17 November 2026.
Ackermans & van Haaren led the round. AbbVie Ventures and M Ventures invested for the first time, and the existing shareholders Bioqube Ventures, Korys and Novo Holdings also took part. Commit did not disclose a valuation.
Most of the money is earmarked for COM002, the company's first development candidate. Commit plans to finish the preclinical studies needed for an Investigational New Drug (IND) application and then file one, which would allow the drug to move into clinical testing.
“Complement is among the immune system’s most potent effector mechanisms yet remains largely untapped in drug development.”Charlotte Kremers, Principal, M Ventures
What Commit Biologics does
Complement is part of the immune system. BioPharm International noted that its classical pathway is set off when the protein C1q binds antibodies clustered on a cell's surface, and that it also helps clear damaged or dying cells. Commit's approach, which it calls BiCE (Bispecific Complement Engager), aims to steer that system against specific cells. According to BioPharm International, the platform turns conventional IgG antibodies into molecules that recruit the complement protein C1q to a target cell. The method does not depend on T cells, and the molecules keep the usual properties of an IgG antibody.
COM002 is a BiCE molecule that binds two targets and is designed to remove selected immune cells in cancer and autoimmune disease. Commit has not said what the two targets are. BioPharm International reported that the first planned indication is relapsed or refractory non-Hodgkin lymphoma, with several autoimmune diseases to follow. It also reported that animal studies in non-human primates, presented in November 2025, showed deep and lasting depletion of B cells without treatment-related safety findings or a systemic cytokine release.
The company has sites in Copenhagen and Aarhus and was spun out of Aarhus University, BioPharm International said. Its founding year and headcount were not disclosed.
Who invested
Ackermans & van Haaren, the lead investor, said it was proud to back the company and believes the platform could create a new approach to immunotherapy, according to investment manager Lenny Van Steenhuyse. Of the two new investors, Charlotte Kremers, a principal at M Ventures, said complement had seen little use in drug development so far despite its strength as an immune mechanism.
After the close, three investor representatives joined Commit's board: Michael Rosenzweig from AbbVie Ventures, Charlotte Kremers from M Ventures and Lenny Van Steenhuyse from Ackermans & van Haaren.
Chief executive Thomas L. F. Montgomery Andresen said the company had been built on the idea that complement could be aimed deliberately at diseased cells, and that the backing of financial and strategic investors for its first candidate was a milestone for the team.
What the money is for
Commit said the round will pay for three things: completing IND-enabling work and filing the IND for COM002, moving a second programme into IND-enabling development, and adding further molecules to the BiCE pipeline. The second programme has not been named.
BioPharm International reported that Commit expects to dose the first patient with COM002 in early 2028. Ahead of the financing, on 12 November, the company named Anne-Marie Levy Rasmussen as chief operating officer and Benjamin Ole Wolthers as head of clinical development, the publication said.
A crowded field in B-cell depletion
COM002 enters a busy area of drug development aimed at depleting B cells. BioPharm International noted that the field has moved from CD20 antibodies towards CAR-T therapies and T-cell engagers, which can clear B cells more thoroughly but carry risks such as cytokine release syndrome. Commit's molecules are designed to deplete target cells without relying on T cells, and its primate studies showed no systemic cytokine release. The publication also pointed out that the BiCE platform has not yet been tested in people, so the case rests on the animal data for now.
Company website: commitbio.com
